Jianfeng Group Lin2016 -020 (Announcement on Resolution of 2015 Annual General Meeting of Shareholders)
Release time:
2020-08-05
2015年年度股东大会决议公告
重要内容提示:
本次会议是否有否决议案:无
一、会议召开和出席情况
(一)股东大会召开的时间:2016年5月9日
(二)股东大会召开的地点:浙江省金华市婺江东路88号尖峰大厦三楼会议室。
(三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况:
| 1、出席会议的股东和代理人人数 | 38 |
| 2、出席会议的股东所持有表决权的股份总数(股) | 57,480,920 |
| 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例(%) | 16.7% |
(四)表决方式是否符合《公司法》及《公司章程》的规定,大会主持情况等。
本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事会 召集,董事长蒋晓萌先生主持。会议的召集、召开符合有关法律、法规、规章和 《公司章程》的规定。
(五)公司董事、监事和董事会秘书的出席情况
1、公司在任董事8人,出席5人,董事长蒋晓萌、董事虞建红、吴光辉、朱林明、独立董事史习民出席了会议,董事杜自弘、独立董事黄从运、吴晓明因出差未能参加会议;
2、公司在任监事5人,出席5人,所有监事参加会议;
3、公司董事会秘书朱坚卫出席了会议;公司高管黄金龙、项崇平、兰小龙列席
二、议案审议情况
(一)非累积投票议案
1、议案名称:2015年度董事会工作报告
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
57,082,110 |
99.30 |
332,710 |
0.57 |
66,100 |
0.13 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,812,810 |
98.83 |
511,310 |
0.88 |
156,800 |
0.29 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,789,910 |
98.79 |
624,910 |
1.08 |
66,100 |
0.13 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,022,215 |
97.46 |
793,766 |
1.38 |
664,939 |
1.16 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,815,510 |
98.84 |
511,310 |
0.88 |
154,100 |
0.28 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,789,910 |
98.79 |
624,910 |
1.08 |
66,100 |
0.13 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,789,910 |
98.79 |
624,910 |
1.08 |
66,100 |
0.13 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,812,810 |
98.83 |
599,310 |
1.04 |
68,800 |
0.13 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
57,107,110 |
99.38 |
201,210 |
0.35 |
152,600 |
0.27 |
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
56,812,810 |
98.83 |
514,010 |
0.89 |
154,100 |
0.28 |
|
议案 |
议案名称 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
||
|
4 |
2015年度利润分配议案; |
458,112 |
23.89 |
793,766 |
41.41 |
664,939 |
34.70 |
|
5 |
聘请公司2016年度审计机构的议案; |
1,251,407 |
65.28 |
511,310 |
26.67 |
154,100 |
8.05 |
|
6 |
对控股子公司提供担保的议案; |
1,225,807 |
63.95 |
624,910 |
32.60 |
66,100 |
3.45 |
|
7 |
与浙江凯恩特种材料股份有限公司互相担保的议案; |
1,225,807 |
63.95 |
624,910 |
32.60 |
66,100 |
3.45 |
|
9 |
关于向天士力集团增资的关联交易议案; |
1,543,007 |
81.34 |
201,210 |
10.60 |
152,600 |
8.06 |
|
10 |
选举孙宏斌先生为公司独立董事 |
1,248,707 |
65.14 |
514,010 |
26.81 |
154,100 |
8.05 |
(三)关于议案表决的有关情况说明
本公司董事长蒋晓萌先生兼任天士力集团董事局副主席,按照《上海证券交易所股票上市规则》有关规定,天士力集团为本公司关联法人,本次增资行为构成关联交易。蒋晓萌先生持有本公司股票20,000股,回避了对第九项议案《关于向天士力集团增资的关联交易议案》的表决。
三、律师见证情况
1、本次股东大会鉴证的律师事务所:浙江一剑律师事务所
律师:陈雄武、朱建辉
2、律师鉴证结论意见:
尖峰集团2015年年度股东大会的召集和召开程序、参加会议人员资格、本次股东大会的议案和表决程序等事宜,均符合法律、法规和公司《章程》的有关规定,本次股东大会的表决结果合法有效。
四、备查文件目录
1、经与会董事和记录人签字确认并加盖董事会印章的股东大会决议;
2、经鉴证的律师事务所主任签字并加盖公章的法律意见书;
3、本所要求的其他文件。
浙江尖峰集团股份有限公司
2016年5月10日
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31